Drugs / W0180
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04564417 | Sep 2020 → Dec 2023 | — | Pierre Fabre Laboratories | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | W0180 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04564417 ↗ |
| Action | Inhibit | “designed to enhance antitumour activities by inhibiting the immunosuppressive role of VISTA in myeloid cells and T cells in solid tumours” PMID 41737913 ↗ Feb 2026 |
| Modality | Monoclonal antibody | “W0180 is a humanised IgG1κ antagonistic monoclonal antibody” PMID 41737913 ↗ Feb 2026 |